CLF1 Antibody

What is CLF1/CLCF1 and what are its biological functions?

CLF1 (Cytokine-like factor 1) is a member of the IL-6 family of cytokines that forms a heteromeric composite cytokine with CLC (Cardiotrophin-like cytokine, also known as novel neurotrophin-1 or B cell stimulating factor-3) . The CLF1/CLC complex requires co-expression for secretion and plays multiple roles in both the nervous and immune systems.

The CLF1/CLC complex functions through binding to membrane-associated CNTF Rα (Ciliary neurotrophic factor receptor alpha), which initiates heterodimerization between gp130 and leukemia inhibitory factor receptor (LIFR), subsequently activating PI 3-kinase and MAP kinase pathways . Biologically, CLF1 supports:

• Survival of embryonic motor and sympathetic neurons

• Induction of astrocyte differentiation from fetal neuroepithelial cells

• Stimulation of B cell proliferation and immunoglobulin production

• Involvement in nervous system development during embryogenesis

CLCF1 mRNA is expressed predominantly in primary and secondary lymphoid organs, with significant upregulation associated with T helper 17 (Th17) cell polarization .

How can researchers detect CLF1 protein expression in cells?

Detection of CLF1 protein expression has been challenging, with most research historically focusing on mRNA levels rather than protein levels. Recent methodological advances include:

Flow Cytometry Protocol for CLF1 Detection:

• Fix and permeabilize cells (essential step as CLF1 is primarily intracellular)

• Use a specific monoclonal antibody directed against CLF1 (such as Clone #138815)

• Detection can be performed through:

  • Indirect method: Using unlabeled anti-CLF1 mAb with a fluorochrome-conjugated secondary anti-mouse IgG

  • Direct method: Using CF405M-conjugated or Alexa Fluor 647-conjugated anti-CLF1 mAb

This protocol has been validated for detection of both human and mouse CLF1, making it versatile for cross-species research applications .

What is the relationship between CLF1 and other cytokine components?

CLF1 exists in functional association with other proteins:

• CLF1/CLC Complex: CLF1 associates with cardiotrophin-like cytokine (CLC) to form the heteromeric composite cytokine CLC/CLF-1 . This complex is required for proper secretion and biological activity.

• Alternative Complex Formation: CLC can alternatively form a composite cytokine with soluble ciliary neurotrophic factor receptor alpha (CNTF Rα) .

• Receptor Binding: Similar to IL-6 and CNTF, CLF1 has three receptor binding sites that interact with its tripartite receptor complex (CNTFRα/LIFRβ/gp130) .

The biological activity of CLF1 is specifically observed only in cells expressing the functional tripartite receptor complex , highlighting the importance of understanding these protein-protein interactions for experimental design.

What challenges exist in detecting CLF1 when it forms complexes with other proteins?

When developing detection protocols for CLF1, researchers should consider several complex-dependent limitations:

• Epitope Masking: The presence of CRLF1 (cytokine receptor-like factor 1) can interfere with CLF1 detection. Flow cytometry experiments revealed that despite using brefeldin A to block CRLF1-induced secretion of CLF1, the cytokine remained undetectable in cells co-expressing both proteins . This suggests that CRLF1 masks the epitope recognized by anti-CLF1 monoclonal antibodies.

• Conformation-Dependent Detection: Since CLF1 interacts with multiple binding partners, the antibody epitope accessibility may vary depending on the conformational state of the protein. This necessitates careful antibody selection for specific research applications.

• Secretion Dynamics: Because CLF1 requires co-expression with either CLF-1 or CNTF Rα for secretion , researchers studying secreted versus intracellular forms must account for these molecular dependencies in experimental design.

These challenges highlight the importance of validating detection methods in the specific experimental context, particularly when studying CLF1 in systems where multiple binding partners may be present.

How do anti-CLF1 antibodies affect the biological activity of the cytokine?

Anti-CLF1 monoclonal antibodies can have functional consequences beyond detection:

• Neutralizing Activity: The anti-CLF1 monoclonal antibody (Clone #138815) inhibits CLF1 biological activity in vitro by binding to an epitope that encompasses site III of the cytokine .

• Mechanism of Inhibition: The antibody blocks the interaction between CLF1 and the receptor signaling chain LIFRβ. Experiments with Ba/F3 cells expressing the three subunits of the CNTFR demonstrated that:

  • 2.5 μg/ml of anti-CLF1 mAb (3.3 molar excess) significantly reduces STAT3 phosphorylation

  • This reduction in receptor activation correlates with decreased CLF1-induced cell proliferation

• Experimental Applications: This neutralizing capacity makes anti-CLF1 antibodies valuable not only for detection but also for functional studies exploring CLF1's role in cellular signaling and physiology.

The dual role of these antibodies (detection and neutralization) provides researchers with versatile tools for both observational and interventional experimental designs.

What experimental models are appropriate for studying CLF1 function?

Several experimental models have been validated for CLF1 research:

• Cell Line Models:

  • Ba/F3 pro-B cell line transduced with CLF1 cDNA for expression studies

  • Ba/F3 cells expressing the three subunits of the CNTFR (CNTFRα/LIFRβ/gp130) for functional assays, as these cells proliferate in response to receptor activation

• Primary Cell Models:

  • Mouse CD4+ T cells cultured under non-polarizing (Th0) or Th1-polarizing conditions have been used to detect CLF1 expression patterns in T cell subpopulations

• Genetic Models:

  • Conditional Clcf1 knockout mouse models provide essential negative controls for antibody specificity validation and facilitate investigation of CLF1's physiological roles

Each model system offers distinct advantages for addressing specific research questions about CLF1 biology, from basic expression analysis to complex functional studies.

How can flow cytometry protocols be optimized for reliable CLF1 detection?

Optimizing flow cytometry for CLF1 detection requires attention to several technical details:

• Fixation and Permeabilization:

  • Complete permeabilization is critical as CLF1 is primarily intracellular

  • Different permeabilization protocols may be required depending on cell type

• Antibody Selection and Validation:

  • Use antibodies validated for flow cytometry applications

  • Confirm specificity through appropriate controls (e.g., Clcf1 knockout cells)

• Detection Methods:

  Detection Approach	Advantages	Considerations
  Indirect (unlabeled primary + fluorochrome-conjugated secondary)	Signal amplification, flexibility	Additional washing steps, potential cross-reactivity
  Direct (fluorochrome-conjugated anti-CLF1 mAb)	Fewer steps, reduced background	Less signal amplification, specific fluorophore required

• Blocking Strategy:

  • When detecting CLF1 in primary immune cells, include Fc receptor blocking to reduce non-specific binding

  • Consider protein complex formation that may mask antibody epitopes

These optimizations ensure reliable detection while minimizing false positives and maximizing signal-to-noise ratio.

What methodologies exist for studying CLF1 in primary immune cells?

Studying CLF1 in primary immune cells requires specialized approaches:

• T Cell Differentiation Protocol:

  • Isolate CD4+ T cells from wild-type or Clcf1 conditional knockout mice

  • Culture under non-polarizing conditions (Th0) or conditions favoring specific T helper cell subtypes (e.g., Th1 polarization with anti-IL-4 and IL-12)

  • After 5 days of culture, cells can be analyzed for CLF1 expression using the optimized flow cytometry protocol

• Validation Strategy:

  • Compare fluorescence signals between wild-type and knockout cells to precisely quantify CLF1-specific expression

  • This approach has successfully detected CLF1 in both Th0 and Th1 cells, validating the use of anti-CLF1 mAb for studying expression patterns in T cell subpopulations

• Functional Assessment:

  • Combine detection with functional readouts (e.g., cytokine production, proliferation)

  • Use neutralizing anti-CLF1 antibodies to assess the functional contribution of CLF1 to immune cell activities

These methodologies provide a comprehensive approach to characterizing both the expression patterns and functional roles of CLF1 in primary immune cells.

How can researchers distinguish between different forms of CLF1 in experimental systems?

CLF1 exists in multiple forms and complexes, which necessitates specific detection strategies:

• Free vs. Complexed CLF1:

  • Current evidence suggests that antibodies against CLF1 may not detect the cytokine when it is complexed with CRLF1, as the epitope becomes masked

  • Differential extraction methods may be required to release CLF1 from complexes

• Secreted vs. Intracellular Forms:

  • Use brefeldin A to block secretion and accumulate intracellular protein for detection

  • Complement intracellular staining with analysis of culture supernatants using techniques like ELISA

• Native vs. Tagged Recombinant Forms:

  • Recombinant systems may utilize protein tags such as His-tag or Protein C tag

  • These can be leveraged for parallel detection with both anti-tag and anti-CLF1 antibodies to confirm identity

This multi-faceted approach allows researchers to comprehensively characterize the different molecular forms of CLF1 present in their experimental systems.

How can CLF1 antibodies be used to investigate signaling pathways?

CLF1 antibodies can be powerful tools for dissecting signaling pathways:

• Receptor Activation Studies:

  • The anti-CLF1 mAb can block STAT3 phosphorylation in receptor-expressing cells

  • This allows for selective inhibition of CLF1-mediated signaling without affecting other cytokines that may signal through shared receptor components

• Dose-Response Analysis:

  • Titration experiments with anti-CLF1 mAb (e.g., 3.3 molar excess shown to significantly reduce signaling) enable quantitative assessment of signaling dependence on CLF1

• Cross-Pathway Interactions:

  • By selectively blocking CLF1 activity, researchers can investigate crosstalk between CLF1-mediated and alternative signaling pathways

These approaches facilitate detailed mechanistic studies of how CLF1 contributes to cellular responses in both physiological and pathological contexts.

What role does CLF1 play in pathological conditions, and how can antibodies help investigate this?

While the search results do not provide comprehensive information on CLF1's role in pathological conditions, some insights can be inferred:

• Fibrotic Diseases:

  • Though not directly addressed for CLF1, the search results mention monoclonal antibodies against other proteins (claudin-1) for treating fibrosis

  • Similar approaches could be investigated for CLF1 given its role in immune modulation

• Immune Dysregulation:

  • Given CLF1's role in B cell proliferation and immunoglobulin production , neutralizing antibodies could be used to investigate its contribution to B cell-mediated pathologies

• Neurological Conditions:

  • CLF1's neurotrophic functions suggest potential roles in neurological disorders

  • Antibody-based targeting could provide insights into therapeutic approaches

Developing research in this area will benefit from the availability of specific antibodies for both detection and functional modulation of CLF1.

What considerations should guide the design of experiments to study CLF1/CLC complexes?

When designing experiments to study CLF1/CLC complexes, several factors require careful attention:

• Complex Formation Dynamics:

  • CLF1 and CLC must be co-expressed for proper complex formation and secretion

  • Experimental systems should account for this dependency when studying either protein individually

• Receptor Engagement:

  • The CLF1/CLC complex binds to membrane-associated CNTF Rα

  • Activity is only observed in cells expressing the complete tripartite receptor complex (CNTFRα/LIFRβ/gp130)

• Antibody Selection:

  • Epitope accessibility may differ between free proteins and complexes

  • Validation should include testing in systems where the proteins exist in various states of complex formation

• Species Considerations:

  • Human and mouse CLF1 share high sequence homology (96%)

  • Antibodies may cross-react, but this should be experimentally validated

These considerations ensure that experiments accurately capture the biological reality of CLF1/CLC complex formation and function.

How are new antibody technologies advancing CLF1 research?

Emerging antibody technologies offer new opportunities for CLF1 research:

• Single B Cell Screening Technologies:

  • These accelerate monoclonal antibody discovery by circumventing the arduous process of generating and testing hybridomas

  • The methodology involves B cell isolation, cell lysis, and sequencing of antibody heavy chain and light chain variable-region genes

  • These genes can then be cloned into mammalian cell lines for antibody production and screening

• Carbohydrate Binding Module-Fused Antibodies:

  • This technology improves the performance of antibodies in applications such as lateral flow immunoassays

  • By fusing a carbohydrate-binding module to detection antibodies, researchers can enhance sensitivity

  • While not specifically applied to CLF1 in the search results, this approach could potentially improve CLF1 detection methodologies

These technological advances may facilitate more sensitive and specific detection of CLF1 in complex biological samples.

What novel approaches might address current limitations in CLF1 research?

Several innovative approaches could address current challenges in CLF1 research:

• Conditional Expression Systems:

  • Development of inducible expression systems for CLF1 and its binding partners

  • This would enable temporal control over complex formation for detailed mechanistic studies

• Proximity Labeling Approaches:

  • Techniques like BioID or APEX2 could identify novel CLF1 interaction partners in living cells

  • These approaches may reveal unknown complexes or signaling components

• Structural Biology Approaches:

  • Determination of the CLF1/CLC complex structure would facilitate epitope mapping

  • This could guide development of antibodies targeting specific functional domains

• Single-Cell Analysis:

  • Application of single-cell technologies to study heterogeneity in CLF1 expression among immune cell populations

  • This may reveal previously unrecognized cellular sources of CLF1

These approaches represent promising directions for advancing our understanding of CLF1 biology beyond current limitations.